Highlights and Quick Summary
- Shareholders Equity (Tangible) for the quarter ending June 30, 2023 was $207 Million (a -14.49% decrease compared to previous quarter)
- Year-over-year quarterly Shareholders Equity (Tangible) decreased by -17.16%
- Annual Shareholders Equity (Tangible) for 2022 was $252 Million (a -31.46% decrease from previous year)
- Annual Shareholders Equity (Tangible) for 2021 was $368 Million (a 7.54% increase from previous year)
- Annual Shareholders Equity (Tangible) for 2020 was $342 Million (a 2339.21% increase from previous year)
Visit stockrow.com/DYN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Shareholders Equity (Tangible) of Dyne Therapeutics, Inc.
Most recent Shareholders Equity (Tangible)of DYN including historical data for past 10 years.Interactive Chart of Shareholders Equity (Tangible) of Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. Shareholders Equity (Tangible) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $206.88 | $241.94 | – | – | – |
| 2022 | $252.36 | $249.74 | $287.06 | $336.46 | $252.36 |
| 2021 | $368.2 | $414.12 | $452.6 | $478.26 | $368.2 |
| 2020 | – | – | $342.37 | $366.85 | $342.37 |
| 2019 | $14.04 | – | – | – | $14.04 |
Business Profile of Dyne Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology